Bioqual, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023
January 23, 2024 at 12:25 pm EST
Share
Bioqual, Inc. reported earnings results for the second quarter and six months ended November 30, 2023. For the second quarter, the company reported sales was USD 15.87 million compared to USD 16.68 million a year ago. Net income was USD 0.484661 million compared to USD 1.29 million a year ago. Basic earnings per share from continuing operations was USD 0.54 compared to USD 1.45 a year ago. Diluted earnings per share from continuing operations was USD 0.54 compared to USD 1.45 a year ago.
For the six months, sales was USD 31.45 million compared to USD 32.49 million a year ago. Net income was USD 1.38 million compared to USD 2.68 million a year ago. Basic earnings per share from continuing operations was USD 1.55 compared to USD 2.99 a year ago. Diluted earnings per share from continuing operations was USD 1.55 compared to USD 2.99 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
